INDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis.

BACKGROUND: Deucravacitinib, a first-in-class, oral, selective TYK2 inhibitor, has redefined systemic therapy options for moderate-to-severe plaque psoriasis. This review synthesizes published data from the POETYK phase 3 and long-term extension (LTE) studies, together with current research and real-world clinical evidence, to provide clinicians a comprehensive perspective on the agent’s long-term efficacy, safety, and clinical utility. OBJECTIVE: To synthesize long-term efficacy and safety data for deucravacitinib and provide practical insights for real-world use. DISCUSSION: We reviewed published, long-term data for 1,519 patients on deucravacitinib over 5,000 person-years of exposure. Sustained clinical response was observed in the efficacy cohort (n=513), with PASI 75/90/100 responses maintained at 67%, 46%, and 22% at week 256 (mNRI). Nearly half of patients achieved minimal disease impact on daily life (DLQI 0/1). Patient-reported outcomes confirmed durable improvement in symptoms, itch, and quality of life. Deucravacitinib demonstrated a consistent safety profile with no new signals in the available long-term data. Rates of adverse and serious adverse events declined over time; acne, when present, was mild and transient. The agent’s selective TYK2 regulatory-domain inhibition distinguishes it mechanistically from broader JAK inhibitors, underpinning its favorable safety and tolerability. CONCLUSIONS: Long-term evidence affirms deucravacitinib’s durable disease control, stable safety, and patient-friendly convenience. With once-daily oral dosing, minimal laboratory monitoring, and efficacy across difficult-to-treat sites, deucravacitinib represents a practical and reliable long-term therapy with oral simplicity for patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2026;25:2(Suppl 1):s3-s10.